Table 6 Averted cervical cancer cases and deaths based on different estimation methods
Number of cases and deaths in each scenario | Model estimated | Calculated | ||
|---|---|---|---|---|
(based on type-specific VE) | (based on 93% VE to CIN3 +   [47]) | |||
No vaccine | HPV-16/18 | HPV-6/11/16/18 | HPV-16/18 | |
95% Vaccine coverage | ||||
Cervical cancer cases | 1370 | 198 | 300 | 160 |
(% of total cervical cancer) | (100.0%) | (14.4%) | (21.9%) | (11.7%) |
Cervical cancer deaths | 722 | 104 | 158 | 84 |
(% of total cervical cancer deaths) | (100.0%) | (14.4%) | (21.9%) | (11.7%) |
80% Vaccine coverage | ||||
Cervical cancer cases | 1370 | 406 | 489 | 351 |
(% of total cervical cancer) | (100.0%) | (29.6%) | (35.7%) | (25.6%) |
Cervical cancer deaths | 722 | 213 | 257 | 185 |
(% of total cervical cancer deaths) | (100.0%) | (29.5%) | (35.6%) | (25.6%) |